Malaria Incidence per Year of Follow-up.

<p>Incidence and relative risk estimated from a Poisson regression model with follow-up time as offset term.</p>*<p>Intention-to-treat analysis uses all evaluable subjects. All malaria episodes subsequent to initial treatment, including non-P. <i>falciparum</i> infections and episodes diagnosed outside of the study clinic, are included, and follow-up time is days from enrollment to date of last contact.</p>†<p>Per-protocol analysis excludes subjects who did not receive full course of treatment, and includes only malaria episodes subsequent to initial treatment caused by P. <i>falciparum</i> mono-infection and diagnosed at the study clinic. Follow-up time is days from enrollment to date of last contact, or receipt of off-study anti-malarial medication.</p

Malaria-free survival from initial episode to first subsequent episode.

<p>CQ, Chloroquine.</p

Consort Diagram.

<p>Consort Diagram.</p

Mean and 95% confidence interval for hemoglobin measured at baseline and routine study follow-up visits.

<p>Mean and 95% confidence interval for hemoglobin measured at baseline and routine study follow-up visits.</p

Demographics and Clinical Characteristics of Initial Malaria Episode.

*<p>7 subjects missing baseline weight and stature measurements.</p>††<p>Peak malaria season is defined as 01 Dec through 31 March.</p

Summary of 28-Day Treatment Outcomes^*.

*<p>WHO 2004 treatment outcome definitions. No subjects experienced late parasitological failure without fever at any episode.</p